Cassie Jung sold $311k of AQST
Chief Operating Officer at Aquestive Therapeutics, Inc.. 62,180 shares at an average of $5.00, traded Sep 4, 2025, filed Sep 8, 2025.
Score components
- +20RoleCOO
- +14Trade size$311k at market
- +5Share of holdings soldSold 18% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001214659-25-013493, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2025 | MOption exercise Common Stock10b5-1 | +25,000 | $3.15 | $79k | 320,526 | Sep 8, 2025 |
| Sep 4, 2025 | MOption exercise Common Stock10b5-1 | +25,000 | $0.71 | $18k | 345,526 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -62,180 | $5.00 | $311k | 283,346 | Sep 8, 2025 |
| Sep 4, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
Related signals
Other insiders at Aquestive Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $120k 25,000 shares | -4% | |
| 0Weak | Aquestive Therapeutics, Inc. | Sherry Korczynski Chief Commercial Officer | $46k 8,750 shares | -4% | |
| 18Weak | Aquestive Therapeutics, Inc. | Peter E. Boyd See Remarks | $70k 10,000 shares | -4% | |
| 21Weak | Aquestive Therapeutics, Inc. | Carl N Kraus Chief Medical Officer | $142k 20,272 shares | -7% | |
| 22Weak | Aquestive Therapeutics, Inc. | Cassie Jung Chief Operating Officer | $474k 67,575 shares | -22% | |
| 11Weak | Aquestive Therapeutics, Inc. | Peter E. Boyd See Remarks | $63k 10,000 shares | -3% | |
| 32Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $551k 91,343 shares | -9% | |
| 13Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $2,400 400 shares | -0% | |
| 19Weak | Aquestive Therapeutics, Inc. | Peter E. Boyd See Remarks | $80k 15,000 shares | -5% | |
| 40Moderate | AQSTsell Aquestive Therapeutics, Inc. | Cassie Jung Chief Operating Officer | $214 44 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.